Kelun-Biotech and Harbour BioMed win NMPA approval for asthma drug
July 16, 2026 | 11:16
Kelun-Biotech and Harbour BioMed, both Hong Kong-listed biopharmaceutical companies, announced China's National Medical Products Administration approved their investigational new drug application for SKB575/HBM7575 to treat asthma.
Mobile Version